CORAL GABLES, Fla., June 28, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that an ePublication on CPP-109 (vigabatrin) describing ocular safety results obtained with CPP-109 (vigabatrin) was published in the June 14, 2012 web edition of the American Journal of Ophthalmology (AJO). These results were obtained from the Company’s previously completed Phase II(a), randomized, double-blind, placebo-controlled trial in cocaine addicted subjects.The paper is entitled, “Visual Field and Ocular Safety during Short-Term Vigabatrin Treatment in Cocaine Abusers” by Tamara L. Berezina, Albert S. Khouri, M. Douglas Winship and Robert D. Fechtner.
